Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,282 across all filing types
Latest filing 2025-10-17 Major Shareholding Noti…
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Certain Securities by Executives and Major Shareholders.' It contains detailed information about share ownership changes by a major shareholder or executive, including dates, share counts, and transaction details. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange, indicating it is a formal disclosure of insider or major shareholder transactions. This matches the definition of 'Major Shareholding Notification' (MRQ), which involves notifications of changes in significant share ownership levels. The document length is 2825 characters, which is consistent with a detailed notification rather than a full report or announcement of a report. Therefore, the correct classification is MRQ.
2025-10-17 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(일반)' which translates to 'Report on Large Shareholding Status (General)'. It contains detailed information about the number of shares held, shareholding ratios, changes in shareholdings, and relationships between shareholders and the company. The document references specific dates for reporting and includes detailed tables of share ownership by various individuals and entities related to the company. There is no indication that this is an announcement of a report publication or a certification. The content is focused on notifying changes in significant share ownership levels, consistent with a Major Shareholding Notification. Therefore, the document fits the category of Major Shareholding Notification (MRQ).
2025-10-14 Korean
투자판단관련주요경영사항 (아이덴젤트(CTP42, 아일리아 바이오시밀러) 미국식품의약국(FDA) 최종 판매 허가 획득)
Regulatory Filings Classification · 95% confidence The document is a brief announcement regarding the final FDA approval for the sale of a product (Eydenzelt, CT-P42, an Eylea biosimilar) by the company. It includes details about the product, approval dates, and future plans for sales. The document is short (1597 characters) and does not contain financial statements, detailed financial analysis, or comprehensive report content. It is an announcement of a significant corporate event related to investment judgment but not a full report or detailed presentation. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-10 Korean
타법인주식및출자증권취득결정(자율공시)(종속회사의주요경영사항)
M&A Activity Classification · 90% confidence The document is a voluntary disclosure by Celltrion regarding its subsidiary’s decision to acquire shares and equity securities of Imclone Systems LLC. It details the target company, acquisition amount, method, board resolution date, and financial summary of the acquired entity. This is an announcement of a corporate takeover/acquisition. According to the taxonomy, announcements related to merger proposals or takeover bids fall under M&A Activity (Code: TAR).
2025-09-23 Korean
[기재정정]투자판단관련주요경영사항 (미국 원료의약품 시설 보유한 기업 인수에 대한 독점 교섭 확약 체결 (우선협상대상자 선정))
M&A Activity Classification · 85% confidence The document is a voluntary corporate disclosure (“투자판단 관련 주요경영사항”) describing the exclusivity agreement and planned acquisition of Imclone Systems LLC by Celltrion USA, Inc. It provides major management details on the M&A transaction (purchase subject, counterparty, acquisition amount) and references the board resolution and due diligence. This is clearly an announcement of an M&A activity rather than a financial report, earnings release, or routine regulatory filing. Therefore it fits the M&A Activity category (Code: TAR).
2025-09-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of the major shareholder (Celltrion Holdings) and its special related parties in the issuing company (Celltrion). This document type is specifically used to notify the market of significant ownership changes and is classified as a Major Shareholding Notification (MRQ).
2025-09-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.